Lipocine plunges after postpartum depression drug fails main goal in late-stage study

Lipocine

02/04/2026 14:09

** Shares of Lipocine LPCN.O plunge 77% to $2.10 premarket

** The biotech firm says its experimental postpartum depression drug missed the main goal in a late‑stage study

** Adds that oral drug LPCN 1154 did not significantly reduce depression scores versus placebo 60 hours after treatment in the full trial

** In a smaller subgroup of patients with prior psychiatric history, drug showed quicker and longer‑lasting symptom improvement in a post‑hoc analysis - LPCN

** Says drug was well tolerated with no serious side effects and no excess sedation or dizziness

** Says it has sought FDA breakthrough therapy and fast‑track status and is weighing further studies or partnerships

** Postpartum depression is a mood disorder that affects women after childbirth, causing persistent sadness, anxiety and difficulty bonding with the baby

** As of last close, stock up ~15% YTD

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))